"We are very excited about the results of our preclinical development, and successful clinical translation of BIND-014. The initial Phase 1 clinical efficacy and safety in advanced and metastatic cancers demonstrate promise for BIND-014 and provide strong validation for our Accurin platform to develop targeted therapeutics that accumulate at the site of disease to maximize therapeutic effect," said Jeff Hrkach, Ph.D., Senior Vice President, Technology Research and Development of BIND Biosciences. "BIND-014 represents the lead Accurin product to enter the clinic from our pipeline and is an ideal example of the power of our proprietary platform to develop targeted therapeutics."
BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle. BIND-014 contains docetaxel, a proven cancer drug which is approved in major cancer indications including breast, prostate and lung, encapsulated in FDA-approved biocompatible and biodegradable polymers. BIND-014 is targeted to prostate specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models, BIND-014 was shown to deliver up to ten-fold more docetaxel to tumors than an equivalent dose of conventional docetaxel. The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in Phase 1 human clinical testing in patients with advanced or metastatic solid tumor cancers (NCT01300533). The early development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program
|Contact: Kathryn Morris|
The Yates Network